Introduction
Signal transducers and activators of transcription (STATs) are a family of seven proteins (STATs 1, 2, 3, 4, 5a, 5b, and 6) unique in their ability both to transduce extracellular signals and regulate transcription directly. STATs transduce extracellular signals from cytokines such as interleukin-6 and interferons or growth factors such as platelet-derived growth factor (PDGF) and epidermal growth factor (EGF). Upon activation of these receptors, STATs are recruited to the plasma membrane where they become activated via phosphorylation of conserved tyrosine residues either directly by receptor tyrosine kinases, for example, PDGF receptor (PDGFR) and EGF receptor (EGFR) or by nonreceptor tyrosine kinases, for example, Src and JAK. Phosphorylated STAT proteins either homo-or heterodimerize via reciprocal phosphotyrosine-SH2 interactions after which the STAT dimers translocate to the cell nucleus where they bind DNA at STAT-specific binding sites.
In normal cells STAT proteins have been identified as important regulators of diverse physiological functions such as immune response, inflammation, proliferation, differentiation, development, cell survival, and apoptosis (Ihle and Kerr, 1995; Schindler and Darnell, 1995; Horvath and Darnell, 1997; Stark et al., 1998) . STAT signaling is tightly regulated in normal cells, either through inhibition of upstream signaling proteins (e.g., internalization of receptors) or negative regulators of Src and JAK proteins, such as SOCS proteins, and Src family and JAK phosphatases (e.g., CD45 and SHP-2) (Irie-Sasaki et al., 2001; Myers et al., 2001; Lefebvre et al., 2003; Lehmann et al., 2003) . STAT proteins have been demonstrated to be directly negatively regulated by SOCs proteins, by protein inhibitors of activated STATs (PIAS ), by SHP phosphatases, and recent evidence has shown both Grb2 and GRIM-19 to be novel regulators of STAT3 activation (Lufei et al., 2003; Zhang et al., 2003; Wormald and Hilton, 2004) . However, in both tumor cells and tissues, disregulation and constitutive activation of STATs, especially STAT3 and STAT5, have been demonstrated to be important to the proliferation and antiapoptotic activity of tumor cells (Bowman and Jove, 1999; Turkson and Jove, 2000) .
STATs have been shown to play active roles at all levels of tumorigenesis. STATs are responsible for generating proproliferative signals (e.g., Cyclin D1, survivin; Sinibaldi et al., 2000; Aoki et al., 2003) and have been shown to upregulate antiapoptotic proteins (e.g., Bcl-XL, Bcl-2; Catlett-Falcone et al., 1999) . In addition, STAT3 has been demonstrated to upregulate VEGF expression, which is necessary for angiogenesis and the maintenance of tumor vasculature (Niu et al., 2002b) . Finally, STAT3 has been implicated in the inhibition of immune responses to tumor growth by blocking expression of proinflammatory factors (Wang et al., 2004) . Unregulated activation of STAT3 and STAT5 has been demonstrated in a variety of tumor types, including breast carcinoma, prostate cancer, melanoma, multiple myeloma, and leukemia among others (Shuai et al., 1996; Garcia et al., 1997 Garcia et al., , 2001 Catlett-Falcone et al., 1999; Mora et al., 2002; Niu et al., 2002a) . Various genetic alterations can lead to constitutive activation of either STAT3 or STAT5 (e.g., overexpression of EGFR and ErbB2; Fernandes et al., 1999; Berclaz et al., 2001) . Autocrine and paracrine production of IL-6 results in activation of STAT3 in prostate cancer and multiple myeloma Mora et al., 2002) , while the oncogene BCR-Abl has been demonstrated to act through constitutive tyrosine phosphorylation of STAT5 in chronic myelogenous leukemia (Shuai et al., 1996) . Various other tyrosine kinases, for example, TEL-JAK2, v-Src, and c-Kit, may require activation of downstream signaling pathways including STAT3 and STAT5 (Yu et al., 1995; Cao et al., 1996; Ning et al., 2001; Spiekermann et al., 2002; Paner et al., 2003) .
On the basis of the importance of STAT3 in tumor progression and survival, we and others recently have begun to focus on STAT3 as a viable molecular target for cancer chemotherapeutics . Several different approaches can be taken for the inhibition of the STAT signaling pathway: targeting receptor-ligand interactions; inhibition of upstream STAT-activating receptor tyrosine kinases and nonreceptor tyrosine kinases; activation of STAT phosphatases and other negative regulators of STATs; and inhibition of STAT dimerization, nuclear translocation, DNA binding, or DNA transcription. Studies with antisense, gene therapy, and RNA interference (siRNA) (Niu et al., 1999 (Niu et al., , 2002b Konnikova et al., 2003) have demonstrated that inhibition of STAT3 signaling suppresses tumor growth and induces apoptosis in cell lines and mouse models, validating STAT3 as a target for molecular intervention. Recently, pharmacological approaches to STAT inhibition have resulted in the identification of peptides capable of blocking STAT dimerization (Turkson et al., 2001 (Turkson et al., , 2004 and identification of the natural product curcumin as an inhibitor of the IL-6/JAK/STAT signaling pathway (Bharti et al., 2003) . Our laboratory has identified the natural product, cucurbitacin I (JSI-124) as a dual inhibitor of phospho-JAK2 and phospho-STAT3 levels in cancer cells (Blaskovich et al., 2003) .
In this paper, structure-activity relationship (SAR) studies have identified cucurbitacin Q (Cuc Q) as an inhibitor of the activation of STAT3 but not JAK2. In contrast, Cuc A was found to be an inhibitor of JAK2 but not STAT3 activation. Furthermore, Cuc Q but not A induces apoptosis and inhibits human tumor growth in mice. Finally, Cuc Q induces apoptosis selectively in tumors that contain constitutively activated STAT3 but not in those tumors without activated STAT3.
Results

Cuc Q selectively suppresses STAT3 but not JAK2 activation in A549 cells
Having previously identified cucurbitacin I (JSI-124) as a potent inhibitor of activation of both JAK2 and STAT3 prompted us to carry out SAR studies to identify agents that are selective for inhibiting the activation of either JAK2 or STAT3. To this end, A549 cells (a human non-small-cell lung carcinoma line) were treated with either vehicle or cucurbitacin analogs A, B, E, I, or Q (10 mM) for 4 h and the cell lysates processed for Western blotting with antiphosphotyrosine STAT3 (Y705) antibody or antiphosphotyrosine JAK2 (Y1007, Y1008) antibody as described under Materials and methods. Figure 1a shows that Cuc Q suppressed the levels of P-STAT3 but had no effect on those of P-JAK2. In contrast, Cuc A suppressed the levels of P-JAK2 but had no effect on those of P-STAT3. Cuc B, E, and I inhibited both P-STAT3 and P-JAK2 levels ( Figure 1a) . The fact that Cuc B, E, I, and Q, but not A, suppressed P-STAT3 levels in A549 cells indicates that addition of a single hydroxyl to carbon 11 of the cucurbitacin pharmacophore results in loss of anti-STAT3 activity (Figure 1a ; compare Cuc A to B). Similarly, the ability of Cuc A, B, E, and I, but not Q, to suppress P-JAK2 levels indicates that simple conversion of the carbon 3 carbonyl in the cucurbitacins to a hydroxyl results in loss of anti-JAK2 activity (Figure 1a ; compare cucurbitacin Q to B).
To confirm that Cuc Q decreases phosphotyrosine levels of STAT3 without affecting total STAT3 levels, we treated A549 cells with either vehicle control or Cuc Q (10 mM) for 4 h, immunoprecipitated the lysates against whole STAT3, then blotted with both P-STAT3 and STAT3 antibodies as described under Materials and methods. Figure 1b shows that Cuc Q treatment suppressed P-STAT3 without affecting total STAT3 levels. We have also shown that treatment of A549 cells with 10 mM Cuc I and A, like Cuc Q, does not affect total STAT3 levels, and none of the three compounds affects total JAK2 levels (data not shown). As further support of the specific antiphosphotyrosine STAT3, but not antiphosphotyrosine JAK2, activity of Cuc Q, we next treated A549 cells as well as two breast carcinoma cell lines (MDA-MB-435 and MDA-MB-468) that also express constitutively activated JAK2 and STAT3, with Cuc Q at various concentrations, and determined IC 50 values of inhibition of STAT3 and JAK2 activation. Table 1 shows that in all three cell lines, Cuc Q is a selective inhibitor of STAT3 activation over JAK2 activation, with IC 50 values of 3.771.7, 0.970.6, and 1.470.7 mM in A549, MDA-MB-435, and MDA-MB-468, respectively. In all three cell lines, JAK2 activation was not inhibited at Cuc Q concentrations as high as 10 mM. Cuc A specifically inhibited JAK2 activation (IC 50 s of 1.570.7, 0.6570.05, and 0.86 mM for A549, MDA-MB-435, and MDA-MB-468, respectively) without affecting STAT3 activation at 10 mM. Cuc I inhibited the activation of both STAT3 and JAK2 but was more potent towards inhibiting JAK2 activation (Table 1) . Thus, in all three cell lines Cuc Q inhibits specifically STAT3 but not JAK2 activation and Cuc A inhibits JAK2 but not STAT3 activation whereas Cuc I inhibits the activation of both STAT3 and JAK2.
Cucurbitacins are highly selective for STAT3 and JAK2 over Src, Akt, Erk, and JNK signaling
We next determined whether the Cuc analogs are selective for the JAK2/STAT3 pathway over other signal transduction pathways. To this end, we treated A549 cells with 10 mM of the different Cuc derivatives and processed the lysates for Western blotting with antibodies specific for phospho-Src, phospho-Erk1/2, phospho-JNK, and phospho-Akt as described under Materials and methods. Figure 1a shows that A549 cells possess constitutively phosphorylated Src, Erk1/Erk2, JNK1, and Akt in addition to phospho-STAT3 and phospho-JAK2. Treatment with Cuc Q, for 4 h at 10 mM significantly blocked STAT3 phosphorylation with little effect on phosphotyrosine levels of JAK2, Src, JNK1, or Akt. In contrast, Cuc A potently inhibited JAK2 phosphorylation, but showed little inhibitory activity against STAT3, Src, JNK1, and Akt. As noted above, the other Cuc compounds were able to inhibit both phosphotyrosine-STAT3 and phosphotyrosine-JAK2 but, like both Cuc Q and A, these compounds showed little inhibitory effect on phosphotyrosine levels of Src, JNK1, and Akt . Interestingly, all of the Cuc analogs significantly increased the levels of phosphorylated Erk1/2 in A549 cells. Thus, these results demonstrate that cucurbitacins are highly selective for inhibition of the JAK/STAT3 pathway activation.
Inhibition of the activation of JAK2, Src, JNK, Akt, and Erk is not required for induction of apoptosis by cucurbitacins
The results of the SAR studies above prompted us to determine whether the ability of the cucurbitacins to induce apoptosis is dependent on suppression of P-JAK2 and/or P-STAT3 levels. To this end, we treated A549 cells with either vehicle control or cucurbitacins (10 mM) for 24 h, harvested the cells, and determined tumor cell death (trypan blue exclusion) and apoptosis (TUNEL) as described under Materials and methods. Figure 1a shows that the most potent inducer of cell death and apoptosis was Cuc Q (60 and 28%, respectively). The least potent was Cuc A (11 and 5%, respectively). Cuc B, E, and I also induced tumor cell death (15-33%) and apoptosis (10-19%). Taken together, the results of Figure 1a demonstrate that decreasing P-JAK2 and increasing P-Erk1/2 levels are not sufficient for significant apoptosis induction, as indicated by the low potency of Cuc A. Furthermore, the results also demonstrate that decreasing the levels of P-JAK2, P-Src, P-JNK, and P-Akt is not required for induction of apoptosis as indicated by the high potency of Cuc Q. Finally, the results also suggest that the ability of the cucurbitacins to induce apoptosis is related to their ability to suppress P-STAT3 but not P-JAK2 levels in A549 cells (compare Cuc Q to A).
Induction of apoptosis by Cuc Q is selective for cells that express constitutively activated STAT3 Figure 2a ). To further confirm that tumor cells that depend on STAT3 for transformation are more sensitive to Cuc Qinduced apoptosis compared to cell lines that do not depend on STAT3, we treated v-Src/3T3 that contain constitutively-activated STAT3, oncogenic H-Ras/3T3, and vector-transfected NIH 3T3 cells that do not (Garcia et al., 1997; Blaskovich et al., 2003) with 10 mM Cuc Q for 24 h. Figure 2b illustrates the results from this experiment. As with the human tumor cell lines, the v-Src/3T3 cell line, with its constitutively activated STAT3, showed a strong induction of apoptosis (from 0.870.9% in control compared to 39.277.3% with Cuc Q treatment, a 50.2-fold increase). In contrast, the H-Ras/3T3 cell line showed significantly less induction of apoptosis (from 0.671.3% in control to only 7.374.7% with Cuc Q treatment, a 12.5-fold increase). In vector/3T3 cells, Cuc Q increased the percentage of apoptotic cells by only 4.2-fold (from 1.771.8% in control to 7.373.9% with Cuc Q treatment) (Figure 2b) . Coupled with the human tumor cell results from Figure 2a , these results demonstrate that Cuc Q selectively induces more apoptosis in cell lines which express activated STAT3 compared to those with little or no STAT3 activation.
Cuc Q inhibits A549 and v-Src transformed NIH 3T3 tumor growth in nude mice
To determine the ability of the cucurbitacin analogs to inhibit tumor growth in vivo, we evaluated the antitumor activity of the cucurbitacin analogs against both A549 and v-Src/3T3 tumors in a nude mouse xenograft model. When the tumors became palpable (at volumes of approximately 100-150 mm 3 ), the mice were treated either with vehicle control or 1 mg/kg/day of the Data are representative of at least three independent experiments, unless otherwise indicated
Inhibition of STAT3 activation with cucurbitacin Q J Sun et al cucurbitacins. Tumor volumes were monitored by caliper measurement as previously described (Blaskovich et al., 2003) and under Materials and methods. Figure 3 shows the antitumor efficacy of the cucurbitacin compounds. With A549 xenografts, all compounds except for Cuc A (11.1% inhibition, P ¼ 0.656) showed statistically significant inhibition of tumor growth. Cuc Q was highly potent, with 73.1% inhibition (P ¼ 0.001) of A549 tumor growth in nude mice ( Figure 3 and Table 2 ). Cuc I was a potent inhibitor of A549 tumor growth with 55.4% inhibition (P ¼ 0.011). Likewise, Cuc B (53.6% inhibition, P ¼ 0.010) and Cuc E (48.5%, P ¼ 0.024) were significant inhibitors of growth of A549 adenocarcinoma in nude mice (Table 2 ). In the v-Src/3T3 xenograft model, again Cuc A treatment did not result in statistically significant inhibition of tumor growth (16%, P ¼ 0.35). As in A549 tumors, Cuc Q was highly potent at inhibiting the growth of v-Src/3T3 tumors. Cuc Q inhibited 57% of tumor growth while Cuc I, B, and E inhibited 45, 40, and 42% of tumor growth, respectively ( Figure 3 and Table 2 ). Taken together, and consistent with the in vitro data of Figure 1a , the results of both xenograft models show that Cuc Q is a potent and significant inhibitor of tumor growth, while Cuc A shows little ability to inhibit tumor growth in either model. Inhibition of STAT3 activity, with or without the ability to inhibit JAK2 activation (as with all cucurbitacins tested but Cuc A), results in antitumor activity, whereas inhibition of JAK2 activity, but not STAT3 activity (as with Cuc A), does not hinder the ability of the tumors to grow on nude mice. These results demonstrate that the ability of the Cuc molecules to inhibit tumor growth is independent of their ability to inhibit JAK2 activation.
Immunohistochemical analysis of tumor sections for STAT3 activation and apoptosis
To determine whether phosphotyrosine STAT3 is targeted by Cuc Q in vivo, and to determine if the results seen in cell culture concerning induction of apoptosis were occurring in tumors from animals treated with Cuc Q, on the termination day of the A549 antitumor experiment, tumors from animals treated with Cuc A, I, and Q, as well as vehicle control, were extracted and fixed in 10% neutral-buffered formalin and then processed into paraffin blocks for tissue sectioning. These tissue sections were stained separately with either TUNEL for determination of apoptosis, or phosphotyrosine STAT3 to determine if the signaling protein is inhibited in the tumors. Results of IHC staining are summarized in Figure 4 . With P-STAT3 staining (Figure 4a ), it is apparent that both Cuc Q and I inhibited STAT3 activation in A549 tumors, with Cuc Q more potent than I (22.677.3% P-STAT3 positive cells for Q and 54.774.5% for I compared to 76.571.4% for control; 70.5 and 28.5% inhibition of phosphotyrosine-STAT3 with Q and I treatment, respectively). Cuc A showed virtually equal staining for phospho-STAT3 as vehicle control (80.871.8% P-STAT3-positive cells), indicating that there was no 
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Discussion
Over the last decade overwhelming evidence has accumulated demonstrating the intimate involvement of STAT3 in malignant transformation and tumor survival. This prompted us and others to develop inhibitors of STAT3 function as novel anticancer drugs. To this end, we have used two approaches, one targeting STAT3 dimerization (Turkson et al., 2001 (Turkson et al., , 2004 ), a step required for STAT3 activation and translocation to the nucleus; and the other, inhibition of the activation of STAT3 by reducing its cellular phosphotyrosine levels (Blaskovich et al., 2003) . Recently, using a phosphotyrosine-STAT3 cytoblot to evaluate the NCI diversity set chemical library, we discovered Cuc I, which inhibited both STAT3 and JAK2 activation (Blaskovich et al., 2003) . In the present study, SAR studies with five cucurbitacin analogs led us to a highly selective STAT3 activation inhibitor, Cuc Q; a highly selective inhibitor of JAK2 activation, Cuc A; and three dual inhibitors, Cuc I, E, and B. From the chemical point of view, these are very important findings that indicate that addition of a single hydroxyl group to carbon 11 of the cucurbitacins results in loss of anti-STAT3 activity, whereas a simple conversion of a carbon 3 carbonyl to a hydroxyl leads to loss of anti-JAK2 activity (see Figure 1 ).
Identifying compounds that are highly selective for either STAT3 or JAK2 allowed us to address important issues concerning the involvement of STAT3 vs JAK2 in human cancer cell survival. Our studies suggest that suppressing STAT3 activation is more detrimental to tumor survival than blocking JAK2 activation. Indeed, both in cultured cells as well as in nude mouse xenografts, Cuc A, which blocks JAK2 but not STAT3 activation, was a poor inducer of apoptosis and an ineffective inhibitor of tumor growth. Furthermore, all three cucurbitacins (Cuc I, E, and B) that inhibit the activation of both STAT3 and JAK2 were less active at inducing apoptosis and inhibiting tumor growth suggesting that inhibition of JAK2 activation may hinder the antitumor activity of cucurbitacins.
Cancer is a result of many genetic alterations resulting in numerous aberrant signal transduction pathways (Hanahan and Weinberg, 2000) . Although activation of STAT3 is a major contributor to malignant transformation, other pathways such as those that mediate the action of the Ras and Src oncoproteins play pivotal roles in oncogenesis and tumor survival. An important question is whether suppression of all aberrant pathways is necessary for inducing tumor cell death. In this paper, we have demonstrated that Cuc Q, I, E, and B induced apoptosis without inhibiting the activation of Src, Akt, Erk1/2, and JNK, suggesting that the suppression of Inhibition of STAT3 activation with cucurbitacin Q J Sun et al STAT3 activation is sufficient for apoptosis induction. This is consistent with the notion that many genetic alterations need to accumulate for cancer development and consequently suppressing one of these could be sufficient for reversal of malignant transformation. The fact that Cuc Q inhibits STAT3 activation whereas Cuc A inhibits JAK2 activation suggests that these compounds have different targets. The actual biochemical targets for cucurbitacins are not known. The lowering of phosphotyrosine levels, suggest that these agents either inhibit upstream tyrosine kinases or activate upstream phosphotyrosine phosphatases. Possible tyrosine kinases that could be targets are the Src family of kinases. Src kinase itself was not inhibited in vitro by Cuc I (Blaskovich et al., 2003) and Q (data not shown). We do not know if other Src kinase family members such as Lyn and Fyn are affected. Similarly, although JAK2 kinase in vitro was not inhibited by Cuc I (Blaskovich et al., 2003) and Q (data not shown), we do not know if other JAKs such as JAK1 are affected. Phosphatases that are known to downregulate STAT3 such as SHP-2 as well as other downregulators of STAT3 such as SOCS and PIAS could also be targets.
Cuc Q and A are chemically very similar (see Figure 1a ), yet their biological and physiological effects are very distinct. Cuc A inhibited JAK2 but not STAT3 activation and was not able to induce apoptosis and inhibit tumor growth of the A549 lung tumors in nude mice. In contrast, Cuc Q inhibited STAT3 but not JAK2 activation and was very potent at inducing apoptosis and at inhibiting A549 tumor growth in the same animal model. Furthermore, in cultured human cancer cells and oncogene-transformed murine cells, Cuc Q induced programmed cell death much more efficiently in those tumors with constitutively activated STAT3. These SAR and in vitro/in vivo studies suggest that inactivation of JAK2 is not sufficient and that selective inhibition of STAT3 with pharmacological agents can lead to tumor cell death. This is consistent with previous studies that demonstrated that a dominant-negative form of STAT3 (STAT3-beta) can induce apoptosis in human cancer cells (Niu et al., 1999; Turkson and Jove, 2000) .
In conclusion, we have discovered compounds that are highly selective for disrupting JAK2 or STAT3 signaling and that can be used as chemical probes to dissect the importance of these signal transduction circuits in normal and pathophysiological conditions. We have used these probes to demonstrate that disruption of STAT3, not JAK2, function is more detrimental to tumor survival. These results give further support for the use of STAT3 as a molecular therapeutic target to combat cancer.
Materials and methods
Cell lines
All human tumor cell lines used were obtained from American Type Culture Collection (Manassas, VA, USA). Stably transfected v-Src/NIH 3T3 cell line has been described earlier .
Cucurbitacin analogs
All cucurbitacin compounds were obtained from the National Cancer Institute: cucurbitacin A (NSC #94743), cucurbitacin B (NSC #49451), cucurbitacin E (NSC #106399), cucurbitacin I (NSC #521777), cucurbitacin Q (NSC #135075).
Western blotting
Treated cell samples were lysed in 30 mM HEPES, pH 7.5, 10 mM NaCl, 5 mM MgCl 2 , 25 mM NaF, 1 mM EGTA, 1% Triton X-100, 10% glycerol, 2 mM sodium orthovanadate, 10 mg/ml aprotinin, 10 mg/ml soybean trypsin inhibitor, 25 mg/ ml leupeptin, 2 mM PMSF, and 6.4 mg/ml p-nitrophenylphosphate. Phospho-STAT3, phospho-AKT, phospho-Src, and phospho-p42/p44 MAPK antibodies were obtained from Cell Signaling Technologies (Cambridge, MA, USA). Phospho-JNK and whole STAT3 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); phospho-JAK2 antibody came from Upstate Biotechnology (Lake Placid, NY, USA). Membranes were blocked in either 5% milk in phosphate-buffered saline (PBS), pH 7.4, containing 0.1% Tween-20 (PBS-T) or 1% BSA in tris-buffered saline (TBS), pH 7.5, containing 0.1% Tween-20 (TBS-T). Phospho-specific antibodies (excepting P-MAPK and P-JNK) were incubated in 1% BSA in TBS-T while all other antibodies were diluted in 5% milk in PBS-T for either 2 h at room temperature or overnight at 41C. HRP-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA) were diluted in 5% milk in either PBS-T or TBS-T at 1 : 1000 dilution for 1 h at room temperature. Western blots were visualized using enhanced chemiluminescence.
STAT3 immunoprecipitation
A549 cells were treated for 4 h with vehicle or Cuc Q, then lysed in 150 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, 10% glycerol, 5 mM NaF, 1 mM DTT, 1 mM PMSF, 2 mM sodium orthovanadate, and 5 mg/ml leupeptin. Sample lysates were collected and cleared, then 500 mg of lysate was immunoprecipitated with 50 ng STAT3 antibody overnight at 41C, then rocked with 25 ml Protein A/G PLUS agarose (Santa Cruz Biotechnology) for 1 h at 41C. Samples were washed four times with lysis buffer, then boiled in 2 Â SDS-PAGE sample buffer and run on 10% SDS-PAGE gel. Protein was transferred to nitrocellulose then blotted as above for both phospho-specific STAT3 and STAT3.
Antitumor activity in the nude mouse tumor xenograft model Nude mice (Charles River, Wilmington, MA, USA) were maintained in accordance with the Institutional Animal Care and Use Committee (IACUC) procedures and guidelines. A549 cells were harvested, resuspended in PBS, and injected subcutaneously (s.c.) into the right and left flank (1 Â 10 7 cells per flank) of 8-week-old female nude mice as reported previously (Blaskovich et al., 2003) . When tumors reached about 150 mm 3 , animals were randomized (four animals per group; two tumors per animal) and dosed intraperitoneally (i.p.) either with cucurbitacin analogs (0.5 or 1 mg/kg/day, i.p.) in 20% DMSO in water or with an equal volume of vehicle control. The tumor volumes were determined by measuring the length (l) and the width (w) and calculating the volume (V ¼ lw 2 /2) as described previously (Blaskovich et al., 2003) . Statistical significance between control and treated animals were evaluated by using Student's t-test.
In vitro cellular proliferation and TUNEL assays Subconfluent A549, MDA-MB-435, MDA-MB-453, MDA-MB-468, v-Src transformed NIH 3T3 (v-Src/3T3), H-Ras transformed NIH 3T3 (H-Ras/3T3), and vector NIH 3T3 cells were grown in the presence of 10 mM cucurbitacin A, I, or Q or DMSO vehicle control. After 24 h, cells were harvested by trypsinization and counted via trypan blue exclusion assay to determine cellular viability. In all, 75 000-150 000 cells (depending on cell line) were then spun onto glass slides using a Cytospin 3 centrifuge (Thermo Shandon Inc., Pittsburgh, PA, USA). After fixing cells to the slides with 4% paraformaldehyde in PBS, pH 7.5, for 1 h at room temperature, cells were labeled for apoptotic DNA strand breaks by TUNEL reaction using an in situ cell death detection kit (Roche Applied Science, Indianapolis, IN, USA) according to the manufacturer's instructions, then mounted in Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA) containing 4 0 ,6-diamidino-2-phenylindole (DAPI) to counterstain DNA. Fluorescein-labeled DNA strand breaks (TUNEL-positive cells) were then visualized using a fluorescent microscope (Leica Microsystems Inc., Bannockburn, IL, USA) and pictures taken with a digital camera (Diagnostic Instruments, Inc., Sterling Heights, MI, USA). TUNELpositive nuclei were counted and compared to DAPI-stained nuclei to determine the percent induction of apoptosis by the different cucurbitacin compounds. Statistical significance between control and treated tumors were evaluated by using Student's t-test.
P-STAT3 immunohistochemistry
On the termination day of the A549 antitumor experiment, tumors were extracted and fixed in 10% neutral-buffered formalin for 6 h. After fixation, the tissue samples were processed into paraffin blocks. Tissue sections (5 mm) were dewaxed with xylene and rehydrated through descending alcohol to deionized water and then placed in PBS. Antigens were retrieved briefly with citrate buffer, pH 6.0, in a microwave followed by a mild trypsinization (0.025% trypsin in 50 mM Tris buffer containing 0.05% calcium chloride, pH 7.6). From this point, all steps were carried out in a DAKO Autostainer (DakoCytomation California, Inc., Carpinteria, CA, USA). Sections were rinsed three times in TBS-Tween buffer, pH 7.6, then endogenous peroxidases were quenched with 3% hydrogen peroxide and nonspecific binding with 2% normal goat serum in 3% BSA/PBS. Sections then were incubated overnight with 1 : 400 phospho-STAT3 (Cell Signaling Technologies) at 41C in a humidified chamber. Detection was performed using the Elite ABC Rabbit kit (Vector Laboratories) and DAB chromogen (DakoCytomation California, Inc.) according to the manufacturer's instructions. Slides were counterstained for 20-30 s with modified Mayer's hematoxylin, dehydrated through ascending alcohol, cleared, and mounted with resinous mounting medium. Quantification was performed by counting both the phospho-STAT3-positive and -negative cells on slides representative of eight tumors and significance was determined by Student's t-test.
TUNEL immunohistochemistry
Tumors were harvested, frozen, and dewaxed as described for P-STAT3 immunohistochemistry. Tissue sections (5 mm) were digested for 10 min with 25 mg/ml proteinase K in PBS and then washed thoroughly. Peroxidases were quenched with 3% hydrogen peroxide in PBS and washed. Sections were equilibrated with equilibration buffer, then incubated in 30% TdT enzymes/70% digoxigenin nucleotidyl reaction buffer for 1 h at 371C in a humidified chamber. The labeling reaction was stopped in stop/wash buffer with moderate shaking. Slides then were placed on the Dako Autostainer and incubated with antidigoxigenin-peroxidase (DakoCytomation California, Inc.) for 30 min using DAB substrate. Sections were counterstained with methyl green (Vector Laboratories), dehydrated through ascending alcohol, cleared, and mounted with resinous mounting medium. The quantification was performed by counting both the TUNEL-positive and -negative cells on slides representative of eight tumors and significance was determined by Student's t-test.
